Siu LL, et al. - In patients with programmed death ligand 1 [PD-L1]–low/negative recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), researchers evaluated the safety and objective response rate of durvalumab combined with tremelimumab. All 3 regimens showed a manageable toxicity profile in patients with R/M HNSCC and low or no PD-L1 tumor cell expression. Durvalumab and durvalumab + tremelimumab were clinically beneficial, with the minimal differences observed between the two.